A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07)

Clinical trial NCT05524545 · COMPLETED

Trial details

NCT number: NCT05524545
Sponsor: ALX Oncology Inc.
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Bladder Cancer Urothelial Carcinoma

Start date: 2022-11-02
Primary completion: 2025-06-27
Enrollment: 36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.